Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Ligand Pharmaceuticals Incorporated

Healthcare US LGND

235.91USD
1.51(0.64%)

Last update at 2026-06-04T20:00:00Z

Day Range

234.42241.10
LowHigh

52 Week Range

49.2494.57
LowHigh

Fundamentals

  • Previous Close 234.40
  • Market Cap1544.52M
  • Volume210386
  • P/E Ratio16.16
  • Dividend Yield-%
  • EBITDA33.89M
  • Revenue TTM118.31M
  • Revenue Per Share TTM6.77
  • Gross Profit TTM 107.34M
  • Diluted EPS TTM5.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 36.01M 47.30M -10.53800M 796.64M 173.33M
Minority interest - - 0.00000M - -
Net income -5.21900M 57.59M -2.98500M 629.30M 143.32M
Selling general administrative 70.06M 57.48M 64.44M 41.88M 37.73M
Selling and marketing expenses - - - - -
Gross profit 143.42M 214.96M 156.00M 108.94M 245.12M
Reconciled depreciation 34.24M 47.17M 27.97M 43.73M 14.72M
Ebit -25.50300M 78.89M 8.55M -5.72100M 163.73M
Ebitda 8.73M 117.20M 31.99M -804.54200M 179.52M
Depreciation and amortization 34.24M 38.31M 23.44M -798.82100M 15.79M
Non operating income net other - -11.97100M -8.96300M 25.31M 57.88M
Operating income -25.50300M 78.89M 8.55M -5.72100M 163.73M
Other operating expenses 193.21M 198.24M 177.69M 126.00M 87.73M
Interest expense 1.80M 18.74M 27.42M 35.74M 48.28M
Tax provision 41.23M -10.28800M -7.55300M 167.34M 30.01M
Interest income 2.05M 0.89M 8.08M 28.43M 14.00M
Net interest income 0.25M -18.74000M -19.34200M -7.31500M -34.27700M
Extraordinary items - - - - -0.60000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 41.23M -10.28800M -7.55300M 167.34M 30.01M
Total revenue 196.25M 277.13M 186.42M 120.28M 251.45M
Total operating expenses 140.38M 136.06M 147.27M 114.66M 81.39M
Cost of revenue 52.83M 62.18M 30.42M 11.35M 6.34M
Total other income expense net 61.51M -31.59700M -19.08800M 802.36M 43.88M
Discontinued operations -28.14200M -19.21500M -9.58300M -9.58300M -
Net income from continuing ops -5.21900M 57.59M -2.98500M 629.30M 143.32M
Net income applicable to common shares -33.36100M 57.59M -2.98500M 629.30M 143.32M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 833.06M 762.67M 1301.38M 1362.29M 1469.31M
Intangible assets 366.90M 10.18M 10.11M 10.98M 20.09M
Earning assets - - - - -
Other current assets 3.84M 3.40M 4.67M 3.82M 4.73M
Total liab 130.71M 165.18M 479.75M 652.76M 702.08M
Total stockholder equity 700.91M 597.49M 821.63M 709.52M 767.23M
Deferred long term liab - - 59.09M 64.60M 32.94M
Other current liab 0.26M 21.04M 22.22M 60.30M 11.20M
Common stock 0.02M 0.00002M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings 503.02M 0.45M 449.09M 391.95M 400.11M
Other liab - 56.03M 101.88M 104.71M 61.75M
Good will 103.37M 448.13M 735.00M 784.99M 305.68M
Other assets - 13.27M 58.78M 62.30M 27.96M
Cash 22.95M 0.05M 19.52M 47.62M 1011.53M
Cash and equivalents - - - - -
Total current liabilities 16.78M 98.81M 41.66M 100.11M 17.00M
Current deferred revenue 1.22M 0.35M 11.00M 29.43M 2.14M
Net debt -16.78900M 87.70M 316.74M 406.91M -362.60300M
Short term debt 0.41M 77.41M 0.05M 6.59M 1.24M
Short long term debt - 76.69M - - -
Short long term debt total 6.17M 87.75M 336.26M 454.53M 648.93M
Other stockholder equity 198.70M 597.04M 373.44M 318.36M 367.33M
Property plant equipment - 27.49M 32.75M 14.43M 7.18M
Total current assets 237.43M 263.60M 464.75M 500.56M 1123.64M
Long term investments 48.32M - - - -
Net tangible assets - 139.18M 76.52M -86.44600M 441.46M
Short term investments 147.35M 0.17M 321.59M 363.57M 58.34M
Net receivables 39.31M 35.04M 91.65M 59.06M 41.75M
Long term debt - - 320.72M 442.29M 638.96M
Inventory 23.97M 13.29M 27.33M 26.49M 7.30M
Accounts payable 14.89M 0.00531M 8.40M 3.78M 2.42M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.81700M -0.00098M -0.91700M -0.80100M -0.21600M
Additional paid in capital - - - - -
Common stock total equity - - 0.02M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - 449.09M 391.95M 400.11M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 21.53M 17.22M 23.25M 18.70M 9.54M
Deferred long term asset charges - - - - -
Non current assets total 595.63M 499.07M 836.63M 861.73M 345.66M
Capital lease obligations 6.17M 11.05M 15.54M 12.24M 11.21M
Long term debt total - - 320.72M 442.29M 638.96M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 163.62M 40.01M 615.67M -326.81700M -405.52600M
Change to liabilities -9.62100M -15.06000M -4.58400M -4.39800M -4.54200M
Total cashflows from investing activities 163.62M 30.52M 231.65M 466.92M -423.26900M
Net borrowings -261.00300M -164.94800M -222.20900M -27.32300M 515.40M
Total cash from financing activities -275.99000M -137.76100M -310.54500M -485.17200M 328.58M
Change to operating activities 6.34M -4.08500M -3.33900M -9.57200M -5.45800M
Net income -33.36100M 57.14M -2.98500M 629.30M 143.32M
Change in cash 25.48M -28.44000M -24.31100M -47.50700M 99.16M
Begin period cash flow 19.52M 47.96M 72.27M 119.78M 20.62M
End period cash flow 45.01M 19.52M 47.96M 72.27M 119.78M
Total cash from operating activities 137.85M 78.80M 54.59M -29.33600M 194.06M
Issuance of capital stock - - - - -
Depreciation 51.37M 50.95M 27.97M 43.73M 14.72M
Other cashflows from investing activities -0.96000M -1.22000M -379.56500M 796.29M -16.85600M
Dividends paid - - - - -
Change to inventory 12.06M -0.42700M -17.79900M -2.06100M -2.55900M
Change to account receivables 55.32M -28.61600M -26.06100M 25.46M -29.54400M
Sale purchase of stock 0.00000M 15.32M -77.99800M -453.04800M -122.86800M
Other cashflows from financing activities -14.98700M 27.19M -0.78900M -4.80100M 669.13M
Change to netincome 47.91M 6.19M -1.82000M -717.86800M 9.08M
Capital expenditures 17.92M 8.76M 4.46M 2.55M 11.89M
Change receivables - -28.61600M -26.06100M 25.46M -29.54400M
Cash flows other operating - -17.97400M 57.59M 2.15M 25.09M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -28.44000M -24.31100M -47.59000M 99.38M
Change in working capital 65.68M -52.16400M -10.06400M -4.21500M -38.85400M
Stock based compensation 60.28M 38.78M 30.73M 24.52M 20.85M
Other non cash items -26.84400M -7.28700M 28.00M -797.49800M 24.29M
Free cash flow 119.93M 70.04M 50.13M -31.88900M 182.17M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LGND
Ligand Pharmaceuticals Incorporated		 1.51 0.64% 235.91 16.16 25.13 13.02 1.91 10.45 7.87
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Ligand Pharmaceuticals Incorporated

555 Heritage Drive, Jupiter, FL, United States, 33458

Key Executives

Name Title Year Born
Mr. Todd C. Davis CEO & Director 1961
Mr. Matthew E. Korenberg Pres & COO 1975
Mr. John L. Higgins Exec. Director 1970
Mr. Octavio Espinoza Chief Financial Officer NA
Simon Latimer Head of Investor Relations NA
Mr. Andrew T. Reardon J.D. Chief Legal Officer NA
Mr. Todd Pettingill Director of Corp. Devel. NA
Ms. Audrey Warfield-Graham Chief People Officer NA
Dr. Keith Marschke Sr. VP of Biology & Scientific Affairs NA
Dr. Vincent D. Antle Sr. VP of Technical Operations & QA - Capitsol 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.